Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
Rebekah WilmingtonArash ArdavaniAmelia SimenaczCarol GreenIskandar IdrisPublished in: Obesity surgery (2023)
Liraglutide 3.0 mg, with lifestyle management, reduced weight and improved glycaemic control. These results support liraglutide's application in certain high-risk populations, including patients waiting for bariatric surgical intervention.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- randomized controlled trial
- type diabetes
- glycemic control
- gastric bypass
- obese patients
- end stage renal disease
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- systematic review
- weight gain
- body mass index
- skeletal muscle
- physical activity
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- adipose tissue
- patient reported